BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
BI-1910 is now the second of the company’s anti-tumour necrosis factor receptor 2 programmes to enter clinical development
Read More
Tag: bioinvent
BioInvent and Transgene and report positive BT-001 data
Tumour treatment among all phase 1a cohorts in were concluded with no safety concerns
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
